CRB Group Fellow James Golden explains why solvent-driven hazardous-material infrastructure can become a major cost driver in oligonucleotide manufacturing facilities.
James Golden
Advertisement
Fellow, Chemical Process
CRB Group
Articles by James Golden
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Using Automation to Enhance Pharmaceutical Manufacturing
2
Munnik Revisits His 2026 Predictions: A Midyear Check-In on Regulatory Reform, Data, and AI in Pharma
3
The FDA Moves to Modernize Drug Manufacturing Registration
4
Can Dostarlimab Replace Surgery for dMMR/MSI-H Rectal Cancer?
5